Info

The biopharmaceutical development program of Targepeutics has a set of platform technologies and compounds that are comparable to those of more mature biopharmaceutical companies. In the next several years, Targepeutics plans to put 19 cancer treatment, imaging and diagnostic compounds into clinical trials. The Company also plans to develop cancer diagnostic test kits and sublicense its asthma treatment technology in this same time frame. Dr. Debinski's ongoing research continues to uncover new and advanced opportunities to treat cancer and other diseases. Targepeutics is excited to have exclusive rights to this technology and looks forward to fully developing its commercial potential.